FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma July 1, 2020 EMA Starts Review of Rucaparib May 19, 2022 Potential Clinical Utility of ctDNA-based Surveillance in Patients Treated with ICI August 12, 2020 We’re asking scientists to tackle 9 of the toughest challenges in... October 14, 2020 Load more HOT NEWS Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’ Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug... Beating the Heat with Beets Texting May Help Reduce Disparities in Colorectal Cancer Screening
